Tamar A. E. de Weert

Tamar A. E. de Weert

Auto-generated profile, based on publicly available information

Tamar A. E. de Weert

Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2025 in Science Advances
Verified
Journal Article
Open access
SKSeok-Young Kim
Seok-Young Kim
TWTamar A. E. de Weert
Tamar A. E. de Weert
MVMarijn Annette Vermeulen
Marijn Annette Vermeulen
FRFemke Cecilia Akke Sipkje Ringnalda
Femke Cecilia Akke Sipkje Ringnalda
LKLennart Kester
Lennart Kester
Hans CleversHans Clevers
Hans Clevers
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare and lethal tumor in adolescent and young adult patients. Now, there is no standard-of-care treatment for these patients. Reliable models that represent this disease and can be used for translational research are scarce. To model SCCOHTs, we have established eight patient-derived tumoroid lines from tumor lesions of three patients with SCCOHT. The tumoroids recapitulate genomic and transcriptomic characteristics of the corresponding patient tumors and capture intrapatient tumor heterogeneity. Organoid drug profiling using a library of 153 clinical compounds identified methotrexate as an effective and selective drug against SCCOHTs with a clinically relevant IC 50 of 35 nanomolars. RNA sequencing demonstrated that methotrexate induced TP53 pathway activation and apoptosis. These data underscore that organoid technology can support the design of therapeutic strategies for rare cancers.